Bio-Path Holdings Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Bio-Path Holdings wird ein Gewinn- und Umsatzwachstum von 47% bzw. 95.3% pro Jahr prognostiziert, während der Gewinn pro Aktie um 48.4% pro Jahr wachsen soll.

Wichtige Informationen

47.0%

Wachstumsrate der Gewinne

48.4%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	28.5%
Wachstumsrate der Einnahmen	95.3%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	21 Aug 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

We're Keeping An Eye On Bio-Path Holdings' (NASDAQ:BPTH) Cash Burn Rate

Nov 05

Bio-Path GAAP EPS of -$0.42 beats by $0.07

Aug 16

Is Bio-Path Holdings (NASDAQ:BPTH) In A Good Position To Deliver On Growth Plans?

Jul 08

Here's Why We're Not Too Worried About Bio-Path Holdings' (NASDAQ:BPTH) Cash Burn Situation

Mar 24

Bio-Path Holdings (NASDAQ:BPTH) Is In A Good Position To Deliver On Growth Plans

Aug 17

We Think Bio-Path Holdings (NASDAQ:BPTH) Needs To Drive Business Growth Carefully

Mar 26

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:BPTH - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	N/A	-14	N/A	N/A	1
12/31/2025	N/A	-13	N/A	N/A	1
12/31/2024	N/A	-13	N/A	N/A	1
6/30/2024	N/A	-12	-9	-9	N/A
3/31/2024	N/A	-14	-9	-9	N/A
12/31/2023	N/A	-16	-12	-12	N/A
9/30/2023	N/A	-17	-15	-15	N/A
6/30/2023	N/A	-17	-15	-15	N/A
3/31/2023	N/A	-16	-16	-16	N/A
12/31/2022	N/A	-14	-15	-15	N/A
9/30/2022	N/A	-14	-13	-13	N/A
6/30/2022	N/A	-13	-12	-12	N/A
3/31/2022	N/A	-11	-11	-11	N/A
12/31/2021	N/A	-10	-10	-10	N/A
9/30/2021	N/A	-9	-10	-10	N/A
6/30/2021	N/A	-10	-9	-9	N/A
3/31/2021	N/A	-10	-10	-10	N/A
12/31/2020	N/A	-11	-11	-11	N/A
9/30/2020	N/A	-11	-11	-11	N/A
6/30/2020	N/A	-10	-10	-10	N/A
3/31/2020	N/A	-10	-9	-9	N/A
12/31/2019	N/A	-9	-8	-8	N/A
9/30/2019	N/A	-8	-7	-7	N/A
6/30/2019	N/A	-9	-7	-7	N/A
3/31/2019	N/A	-8	-6	-6	N/A
12/31/2018	N/A	-9	-6	-6	N/A
9/30/2018	0	-9	-7	-7	N/A
6/30/2018	0	-8	-7	-7	N/A
3/31/2018	0	-10	N/A	-8	N/A
12/31/2017	0	-8	N/A	-8	N/A
9/30/2017	0	-7	N/A	-7	N/A
6/30/2017	0	-6	N/A	-8	N/A
3/31/2017	0	-5	N/A	-8	N/A
12/31/2016	0	-7	N/A	-8	N/A
9/30/2016	N/A	-7	N/A	-8	N/A
6/30/2016	N/A	-7	N/A	-7	N/A
3/31/2016	N/A	-6	N/A	-6	N/A
12/31/2015	N/A	-5	N/A	-5	N/A
9/30/2015	N/A	-6	N/A	-5	N/A
6/30/2015	N/A	-5	N/A	-5	N/A
3/31/2015	N/A	-5	N/A	-5	N/A
12/31/2014	N/A	-5	N/A	-4	N/A
9/30/2014	N/A	-4	N/A	-3	N/A
6/30/2014	N/A	-4	N/A	-3	N/A
3/31/2014	N/A	-3	N/A	-2	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: BPTH wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: BPTH wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: BPTH wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: BPTH wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Hohe Wachstumseinnahmen: BPTH wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von BPTH in 3 Jahren voraussichtlich hoch sein wird

Bio-Path Holdings Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

No longer forecast to breakeven

Price target decreased by 7.7% to US$12.00

Forecast to breakeven in 2025

Price target decreased to US$11.00

Price target decreased to US$11.00

Price target increased to US$12.50

Recent updates

Bio-Path Holdings Receives Non-Compliance Letter from Nasdaq Regarding Minimum Stockholders’ Equity Requirement

Bio-Path Holdings, Inc. Reports Solid Tumor Patient Response Supporting BP1001-A's Compelling Potential as Treatment for Advanced Solid Tumors

New major risk - Financial position

Bio-Path Holdings, Inc. to Report Q2, 2024 Results on Aug 15, 2024

Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia At European Hematology Association Congress

Bio-Path Holdings, Inc. announced that it expects to receive $4.000001 million in funding

New major risk - Negative shareholders equity

Bio-Path Holdings, Inc. to Report Q1, 2024 Results on May 15, 2024

Bio-Path Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $1.209375 million.

Bio-Path Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $1.209375 million.

New major risk - Share price stability

Bio-Path Holdings, Inc. Announces Successful Completion of Higher Dose Second Cohort in Phase 1/1B Clinical Trial of Bp1002 in Refractory/Relapsed Acute Myeloid Leukemia (AML) Patients

Bio-Path Holdings, Inc. Expands Global Patent Portfolio

Bio-Path Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $2 million.

New minor risk - Profitability

Bio-Path Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $0.29925 million.

Bio-Path Holdings, Inc. has withdrawn its Follow-on Equity Offering in the amount of $7.499995 million.

Bio-Path Holdings Receives Deficiency Letter from the Listing Qualifications Department of the Nasdaq Regarding Listing Rule 5550(b)(1)

Bio-Path Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $7.499995 million.

Bio-Path Holdings, Inc. to Report Q4, 2023 Results on Mar 08, 2024

Bio-Path Holdings, Inc. has withdrawn its Follow-on Equity Offering in the amount of $23.75 million.

New major risk - Share price stability

Bio-Path Holdings Announces Completion of First Dose Cohort in Phase 1 Clinical Trial Evaluating BP1002 to Treat Refractory/Relapsed Lymphoma and Refractory/Relapsed Chronic Lymphocytic Leukemia Patients

Bio-Path Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $19 million.

Bio-Path Holdings Successfully Completes First Dose Cohort of Phase 1/1B Clinical Trial of Bp1002 in Refractory/Relapsed Acute Myeloid Leukemia

No longer forecast to breakeven

Bio-Path Holdings, Inc. to Report Q3, 2023 Results on Nov 15, 2023

Bio-Path Holdings, Inc., Annual General Meeting, Dec 14, 2023

Bio-Path Holdings, Inc. Receives Non-Compliance Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Price target decreased by 7.7% to US$12.00

Bio-Path Holdings, Inc. to Report Q2, 2023 Results on Aug 15, 2023

New major risk - Shareholder dilution

New major risk - Share price stability

Bio-Path Holdings, Inc. Announces Positive Results from Interim Analysis of Phase 2 Clinical Trial of Prexigebersen in Acute Myeloid Leukemia

New major risk - Market cap size

New minor risk - Share price stability

Bio-Path Holdings, Inc. to Report Q1, 2023 Results on May 12, 2023

Forecast to breakeven in 2025

Bio-Path Holdings, Inc. Announces First Patient Dosed in Phase 1/1b Clinical Trial of BP1001-A in Solid Tumors

Price target decreased to US$11.00

Bio-Path Holdings, Inc. to Report Q3, 2022 Results on Nov 15, 2022

We're Keeping An Eye On Bio-Path Holdings' (NASDAQ:BPTH) Cash Burn Rate

Bio-Path Holdings, Inc., Annual General Meeting, Dec 15, 2022

Bio-Path Holdings, Inc. Announces First Patient Dosed in Phase 1/1b Study of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia Patients

Bio-Path GAAP EPS of -$0.42 beats by $0.07

Bio-Path Holdings, Inc. to Report Q2, 2022 Results on Aug 16, 2022

Is Bio-Path Holdings (NASDAQ:BPTH) In A Good Position To Deliver On Growth Plans?

Price target decreased to US$11.00

Bio-Path Holdings, Inc. to Report Q1, 2022 Results on May 17, 2022

Price target increased to US$12.50

Less than half of directors are independent

Bio-Path Holdings Presents BP1003 Data at 2022 American Association for Cancer Research Annual Meeting

Bio-Path Holdings, Inc. Appoints Aline Sherwood to its Board of Directors

Here's Why We're Not Too Worried About Bio-Path Holdings' (NASDAQ:BPTH) Cash Burn Situation

Bio-Path Holdings, Inc. to Report Fiscal Year 2021 Results on Mar 11, 2022

Insufficient new directors

Bio-Path Holdings, Inc. Announces Resignation of Martina Molsbergen as Member of the Board and All Committees of the Board

Bio-Path Holdings, Inc. Presents Data from Ongoing Phase 2 Study of Prexigebersen At 2021 American Society of Hematology Annual Meeting

Bio-Path Holdings Announces Clearance of Investigational New Drug Application for BP1002 in Refractory/Relapsed Acute Myeloid Leukemia Patients

Bio-Path Holdings (NASDAQ:BPTH) Is In A Good Position To Deliver On Growth Plans

Price target increased to US$12.50

We Think Bio-Path Holdings (NASDAQ:BPTH) Needs To Drive Business Growth Carefully

Bio-Path Holdings, Inc. to Report Fiscal Year 2020 Results on Mar 10, 2021

New 90-day high: US$4.55

Will Bio-Path Holdings (NASDAQ:BPTH) Spend Its Cash Wisely?

Bio-Path Holdings Announces First Patient Dosed in Phase 1 Clinical Trial of BP1002

Dosing underway in Bio-Path's early-stage BP1002 study

Bio-Path EPS beats by $0.07

Bio-Path Holdings, Inc. to Report Q3, 2020 Results on Nov 13, 2020